Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

126.62 +0.28 (+0.22%)
Streaming Delayed Price Updated: 10:42 AM EDT, Jul 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
75 76 Next >
News headline image
Arcus (RCUS) Q2 Revenue Jumps 310% ↗
Via The Motley Fool
News headline image
Gilead Sciences's Earnings Outlook ↗
 
Via Benzinga
News headline image
Gilead Sciences Inc (NASDAQ:GILD) Meets Caviar Cruise Quality Investing Criteria ↗
The Caviar Cruise strategy identifies high-quality stocks like Gilead Sciences (GILD) for long-term investment, focusing on strong growth, ROIC, low debt, and solid cash flow. GILD excels in... 
Via Chartmill
Topics Economy
News headline image
Gilead Sciences (GILD) Reports Q2: Everything You Need To Know Ahead Of Earnings
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting results this Thursday after market close. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence World Trade
News headline image
Tango (TNGX) Q2 Revenue Drops 52% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Price Over Earnings Overview: Gilead Sciences ↗
 
Via Benzinga
News headline image
GILEAD SCIENCES INC (NASDAQ:GILD) Shows Strong Technical Breakout Potential with High Ratings ↗
Gilead Sciences (GILD) shows strong technical breakout potential with a high Technical Rating (10) and Setup Rating (8), indicating upward momentum and consolidation before a possible breakout. 
Via Chartmill
News headline image
Gilead Sciences Reports Earnings Thursday. Can The Highly Ranked Drugmaker Beat Its 237% Profit Surge Last Quarter? ↗
The upgraded score means Gilead is now outperforming 96% of all stocks in terms of the most important stock-picking criteria. 
Via Investor's Business Daily
News headline image
Pheton Holdings Dismisses Rumors Of Acquisition By Gilead, But Retail’s Extremely Optimistic ↗
pheton-holdings-dismisses-rumors-of-acquisition-by-gilead 
Via Stocktwits
Topics Government
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch ↗
Via Stocktwits
Topics Government
News headline image
Chinese Health Care Stock Pheton Holdings Collapses After Short Seller Warns Of Manipulation By 'Overseas Scammers' ↗
 
Via Benzinga
News headline image
Why Gilead Sciences Stock Slipped Today ↗
Changes in a federal healthcare authority could negatively impact one of the company's important businesses. 
Via The Motley Fool
News headline image
BMO Capital Has An Important Take On Gilead Sciences, Retail’s Keeping The Optimism Alive ↗
The Supreme Court's Braidwood decision only concretized the power of the Department of Health and Human Services to decide what is necessary preventative care, rather than outright protecting... 
Via Stocktwits
News headline image
Visa, Disney, Blackstone And A Health Care Stock On CNBC's 'Final Trades' ↗
Visa, which will report third quarter results on Tuesday, July 29, is analyst Stephanie Link's final trade. 
Via Benzinga
News headline image
Why Gilead Sciences (GILD) Stock Is Up Today
Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 3% in the afternoon session after its long-acting HIV prevention injection, lenacapavir, received a recommendation for approval... 
Via StockStory
Topics Stocks World Trade
News headline image
Why Gilead Sciences Stock Just Popped ↗
Gilead stock is flashing "buy" in bright green letters. 
Via The Motley Fool
News headline image
Gilead's Newly Approved HIV Prevention Drug Poised To Add Billions To Future Sales ↗
Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, exceeding prior estimates. 
Via Benzinga
News headline image
This Gilead Sciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗
 
Via Benzinga
News headline image
Gilead Gets Analyst Thumbs Up On Market Potential Of HIV-Prevention Injection, But Retail’s Not Ready To Cheer Yet ↗
Needham has a $133 price target on the stock, representing an upside of about 17.5% to the stock’s closing price on Thursday. 
Via Stocktwits
Topics Workforce
News headline image
Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences to Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025
From Gilead Sciences, Inc.
Via Business Wire
News headline image
1 Value Stock Worth Your Attention and 2 Facing Headwinds
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
Topics Supply Chain
News headline image
Director Sells 11,136 Shares of SRRK, a Stock Up 330% in Past Year ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Gilead Sciences, Omnicom Group, and QuinStreet Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after a new trade agreement between the United States and Japan spurred a broad market rally. 
Via StockStory
Topics Stocks World Trade
News headline image
NAFA Publishes New Fleet Safety Guidebook Aimed  at Developing Safety-First Culture in all Organizations
Comtex News Network, Inc. is a content specialist offering actionable news distribution, global syndication, and traffic for your content 
Via News Direct
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
From Pomerantz LLP
Via GlobeNewswire
News headline image
2 Large-Cap Stocks to Consider Right Now and 1 That Underwhelm
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth... 
Via StockStory
Topics Supply Chain
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
From Pomerantz LLP
Via GlobeNewswire
Expanding the Preventive Care Frontier: Dr. Reddy’s Launches Sanofi’s Beyfortus® in India
Via AB Newswire
Topics Death
News headline image
Q1 Earnings Roundup: Gilead Sciences (NASDAQ:GILD) And The Rest Of The Therapeutics Segment
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Gilead Sciences (NASDAQ:GILD) and its peers. 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
75 76 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.